Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis ...

DJ Naves and Lunga Mlandu (Mamelodi Sundowns) and Soyeon Lee and Yisoo Kim (Ulsan HD) - spent three days in Dortmund. In ...

The Global 3D Cell Culture Market is expected to witness a double-digit growth rate by 2027. Some of the key factors driving ...

RIC Energy (Madrid, Spain) and Siemens AG (Munich, Germany) have signed a Memorandum of Understanding (MoU) to jointly ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Modern vehicles, especially EVs and high-end passenger cars, are being equipped with rear fire wipers, advanced aerodynamic ...

According to Sky Germany, Sebastian Kehl met with Jobe Bellingham in Ibiza this week as Dortmund continue their interest.In a ...

Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...